Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated with Favipiravir (T-705) - Sierra Leone, 2014

Clinical Infectious Diseases

Volumn 63, Issue 10, 2016, Pages 1288-1294

  Bai, Chang Qing ^a   Mu, Jin Song ^b   Kargbo, David ^c   Song, Ya Bin ^d   Niu, Wen Kai ^a   Nie, Wei Min ^b   Kanu, Alex ^e   Liu, Wei Wei ^a   Wang, Yao Ping ^f   Dafae, Foday ^c   Yan, Tao ^b   Hu, Yi ^d   Deng, Yong Qiang ^d   Lu, Hui Jun ^g   Yang, Fan ^h   Zhang, Xiao Guang ⁱ   Sun, Yang ^g   Cao, Yu Xi ⁱ   Su, Hao Xiang ^h   Sun, Yu ^f   Liu, Wen Sen ^g   Wang, Cheng Yu ^g   Qian, Jun ^g   Liu, Liu ^a   Wang, Hong ^d   Tong, Yi Gang ^d   Liu, Ze Yuan ^a   Chen, Yun Song ^a   Wang, Hong Quan ^d   Kargbo, Brima ^c   Gao, George F ^j   Jiang, Jia Fu ^d   more..

^a Sierra Leone Ministry of Health and Sanitation ^*  (China)

^b BEIJING 302 HOSPITAL   (China)

^c Sierra Leone Ministry of Health and Sanitation   (Sierra Leone)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^e Sierra Leone China Friendship Hospital   (Sierra Leone)

^f Kingharman Road Hospital   (Sierra Leone)

^g Key Laboratory of Jilin Province for Zoonosis Prevention and Control   (China)

^h PEKING UNION MEDICAL COLLEGE   (China)

ⁱ Institute for Viral Disease Control and Prevention   (China)

^j CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

more..

Author keywords

clinical features; Ebola virus disease; favipiravir; Sierra Leone; treatment

Indexed keywords

AMODIAQUINE; AMOXICILLIN; ARTESUNATE; AZITHROMYCIN; CIPROFLOXACIN; DIAZEPAM; FAVIPIRAVIR; FUROSEMIDE; LOPERAMIDE; LORATADINE; METOCLOPRAMIDE; MORPHINE; ONDANSETRON; ORAL REHYDRATION SOLUTION; TETRACYCLINE; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ADULT; ANAPHYLAXIS; ANXIETY DISORDER; ARTICLE; CASE FATALITY RATE; CONTROLLED STUDY; CONVULSION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HYPOVOLEMIA; MAJOR CLINICAL STUDY; MALARIA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIERRA LEONE; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD; VITAMIN SUPPLEMENTATION; VOMITING; WORLD HEALTH ORGANIZATION; ADOLESCENT; HEMORRHAGIC FEVER, EBOLA; KAPLAN MEIER METHOD; MORTALITY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AMIDES; ANTIVIRAL AGENTS; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PYRAZINES; RETROSPECTIVE STUDIES; SIERRA LEONE; VIRAL LOAD; YOUNG ADULT;

EID: 84994408776     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw571     Document Type: Article

References (27)

1. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-25.
2. World Health Organization. Ebola situation report-6 January 2016. Available at: http://apps.who.int/ebola/sites/default/files/atoms/files//who-ebola-situation- report-06-01-2016.pdf2016. Accessed 30 January 2016.
3. Briand S, Bertherat E, Cox P, et al. The international Ebola emergency. N Engl J Med 2014; 371:1180-3.
4. Carod-Artal FJ. Illness due the Ebola virus: epidemiology and clinical manifestations within the context of an international public health emergency. Rev Neurol 2015; 60:267-77.
5. Schibler M, Vetter P, Cherpillod P, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis 2015; 15:1034-40.
6. Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 2015; 3:554-62.
7. Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 2015; 49:196-206.
8. Butler D. Ebola drug trials set to begin amid crisis. Nature 2014; 513:13-4.
9. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-54.
10. MediVector, Inc. A phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of favipiravir in adult subjects with uncomplicated influenza. Available at: https://www.clinicaltrials.gov./ct2/show/ NCT02008344?term=favipiravir&rank=3. Accessed 30 January 2016.
11. Toyama Chemical Co Ltd. The New Drug Application approval of "AVIGAN® Tablet 200 mg" in Japan for the anti-influenza virus drug. Available at: https:// www.toyama-chemical.co.jp/eng/news/news140324e.html. Accessed 30 January 2016.
12. Oestereich L, Rieger T, Neumann M, et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 2014; 8:e2804.
13. Smither SJ, Eastaugh LS, Steward JA, et al. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014; 104:153-5.
14. Oestereich L, Lüdtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014; 105:17-21.
15. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 2014; 345:1369-72.
16. Gao GF, Feng Y. On the ground in Sierra Leone. Science 2014; 346:666.
17. World Health Organization. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. Geneva, Switzerland: WHO, 2014.
18. Lu HJ, Qian J, Kargbo D, et al. Ebola virus outbreak investigation, Sierra Leone, September 28-November 11, 2014. Emerg Infect Dis 2015; 21:1921-7.
19. Kilgore PE, Grabenstein JD, Salim AM, et al. Treatment of Ebola virus disease. Pharmacotherapy 2015; 35:43-53.
20. Thi EP, Mire CE, Lee ACH, et al. Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates. Nature 2015; 521: 362-5.
21. Dunning J, Sahr F, Rojek A, et al. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med 2016; 13: e1001997.
22. Gretchen V, Kai K. In setback for potential Ebola drug, company halts trial. Science 2015.
23. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proofof-concept trial in Guinea. PLoS Med 2016; 13:e1001967.
24. Mentré F, Taburet AM, Guedj J, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 2015; 15:150-1.
25. Van Herp M, Declerck H, Decroo T. Favipiravir-A prophylactic treatment for Ebola contacts? Lancet 2015; 385:2350.
26. Bouazza N, Treluyer JM, Foissac F, et al. Favipiravir for children with Ebola. Lancet 2015; 385:603-4.
27. World Health Organization Ebola Response Team. Ebola virus disease in West Africa\-The first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371:1481-95.